Resveratrol Alleviates Liver Fibrosis by Targeting Cross‐Talk Between TLR2/MyD88/ERK and NF‐κB/NLRP3 Inflammasome Pathways in Macrophages
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70208 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Jin-Qing Lei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Toll-Like Receptor 2, NLR Family, Pyrin Domain-Containing 3 Protein, Resveratrol, Inflammasomes. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: This work was supported by the National Natural Science Foundation of China (81860116, 82260109 and 81960119); National Natural Science Foundation of Guangxi (….
Abstract (Originalsprache)
Resveratrol alleviates liver fibrosis in mice by upregulating IL‐10 to reprogram the macrophage phenotype; however, the mechanism remains to be elucidated. Building on our previous work, in this study, we aimed to determine the role of the TLR2/MyD88/ERK and NF‐κB/NLRP3 inflammasome pathways in mediating the effects of resveratrol on liver fibrosis and macrophage polarization. We investigated the expression of cytokines in these inflammasome pathways in a mouse model of liver fibrosis and resveratrol‐treated macrophages. The results showed that expression of TLR2, MyD88, ERK, and NF‐κB1 in liver tissues was increased in the fourth week after treatment with resveratrol but decreased in the fifth week. Similar results were obtained for the NF‐κB/NLRP3 inflammasome pathway. The results also showed that cytokines in both the TLR2/MyD88/ERK and NF‐κB/NLRP3 inflammasome pathways in macrophages were elevated after 24 h and reduced after 36 h of treatment with resveratrol. Immunofluorescence and nucleocytoplasmic separation assays showed that resveratrol inhibited the translocation of NF‐κB from the cytoplasm to the nucleus in macrophages, and increased NF‐κB1 was associated with inhibition of the TLR2/MyD88/ERK pathway. Silencing NF‐κB1 increased the expression of TLR2, MyD88, and ERK. In conclusion, the TLR2/MyD88/ERK and NF‐κB/NLRP3 inflammasome pathways are involved in the effect of resveratrol on macrophage polarization and the subsequent modulation of liver fibrosis. NF‐κB1 acts as the common cytokine that coordinates the crosstalk between the two pathways. Our findings highlight the potential of the members of these pathways as therapeutic targets toward the treatment of liver fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
- Department of Gastroenterology, the Second Affiliated Hospital of Guangxi Medical University, Nanning, China.
Förderung
- This work was supported by the National Natural Science Foundation of China (81860116, 82260109 and 81960119); National Natural Science Foundation of Guangxi (…
Zitieren
APA
Lei, J. Q., Xie, Q. L., Li, Q. P., Qin, S. Y., Wu, J. H., Jiang, H. X., Yu, B., & Luo, W. (2025). Resveratrol Alleviates Liver Fibrosis by Targeting Cross‐Talk Between TLR2/MyD88/ERK and NF‐κB/NLRP3 Inflammasome Pathways in Macrophages. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70208
Vancouver
Lei JQ, Xie QL, Li QP, Qin SY, Wu JH, Jiang HX, et al. Resveratrol Alleviates Liver Fibrosis by Targeting Cross‐Talk Between TLR2/MyD88/ERK and NF‐κB/NLRP3 Inflammasome Pathways in Macrophages. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70208
BibTeX
@article{Lei2025,
author = {Lei, Jin-Qing and Xie, Qing-Li and Li, Qing-Ping and Qin, Shan-Yu and Wu, Jiao-Hua and Jiang, Hai-Xing and Yu, Bing and Luo, Wei},
title = {Resveratrol Alleviates Liver Fibrosis by Targeting Cross‐Talk Between TLR2/MyD88/ERK and NF‐κB/NLRP3 Inflammasome Pathways in Macrophages},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70208}
}
EUVIMED